Chinook Therapeutics, Inc. (KDNY)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Eric L. Dobmeier
Employees:
140
740 HEINZ AVENUE, BERKELEY, CA 94710
510-848-4400

Chinook Therapeutics focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases.

Data derived from most recent annual or quarterly report
Market Cap 3.262 Billion Shares Outstanding80.76 Million Avg 30-day Volume 2.629 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.94
Price to Revenue470.2624 Debt to Equity0.0 EBITDA-249.406 Million
Price to Book Value7.7038 Operating Margin-4302.0687 Enterprise Value2.405 Billion
Current Ratio5.821 EPS Growth-2.854 Quick Ratio5.722
1 Yr BETA 1.1212 52-week High/Low 40.51 / 18.34 Profit Margin-4199.9316
Operating Cash Flow Growth-69.6425 Free Cash Flow to Firm (FCFF) TTM -132.673 Million Free Cash Flow to Equity (FCFE) TTM-178.738 Million
Altman Z-Score9.8924
View SEC Filings from KDNY instead.

View recent insider trading info

Chinook Therapeutics, Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding KDNY (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding KDNY

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-08-11 by THOMAS DOLCA
  • 4: filed on 2023-08-11 by OXTOBY ANDREW
  • 4: filed on 2023-08-11 by KRISHNAN MAHESH
  • 4: filed on 2023-08-11 by KING ANDREW JAMES
  • 4: filed on 2023-08-11 by FROHLICH TOM
  • 4: filed on 2023-08-11 by JEREL DAVIS
  • 4: filed on 2023-08-11 by AZELBY ROBERT
  • 4: filed on 2023-08-01 by KING ANDREW JAMES
  • 4: filed on 2023-05-31 by HAGHIGHAT ROSS
  • 4: filed on 2023-05-31 by JEREL DAVIS

    • Events (8k)

  • 8-K: filed on 2023-08-11:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-03:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-07-28:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-20:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-15:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-06-12:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-12:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-13:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-13:
    Item 7.01: Regulation FD Disclosure

    • Proposed Sales (Form 144)

  • 144: filed on 2023-04-24:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BJERKHOLT ERIC CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-08-11 3

    DOBMEIER ERIC PRESIDENT, CEO

    • Officer
    • Director
    		 0 2023-08-11 5

    GRIFFIN MICHELLE RENEE

    • Director
    		 0 2023-08-11 2

    AKKARAJU SRINIVAS

    • Director
    		 0 2023-08-11 2

    GREENMAN WILLIAM MARINER

    • Director
    		 0 2023-08-11 2

    AZELBY ROBERT

    • Director
    		 0 2023-08-11 3

    JEREL DAVIS

    • Director
    		 0 2023-08-11 5

    OXTOBY ANDREW CHIEF COMMERCIAL OFFICER

    • Officer
    		 0 2023-08-11 3

    THOMAS DOLCA

    • Director
    		 0 2023-08-11 2

    KING ANDREW JAMES CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2023-08-11 6

    FROHLICH TOM CHIEF OPERATING OFFICER

    • Officer
    		 0 2023-08-11 4

    KRISHNAN MAHESH

    • Director
    		 0 2023-08-11 2

    HAGHIGHAT ROSS

    • Director
    		 124,546 2023-05-26 1

    VERSANT VENTURE CAPITAL VII, L.P.

    VERSANT VOYAGEURS I, L.P.

    VERSANT VOYAGEURS I PARALLEL, L.P.

    • 10% Owner
    		 5,328,416 2022-04-04 0

    GLICKLICH ALAN CHIEF MEDICAL OFFICER

    • Officer
    		 29,510 2022-02-10 0

    ISAACS STEPHEN T PRESIDENT AND CEO

    • Officer
    • Director
    		 288,098 2020-09-15 0

    TEMPLEMAN BLAINE CHIEF LEGAL OFFICER

    • Officer
    		 121,916 2020-09-15 0

    FERBER CELESTE SVP, GC AND SECRETARY

    • Officer
    		 38,687 2020-09-15 0

    NUYTEN DIMITRY SA CHIEF MEDICAL OFFICER

    • Officer
    		 8,462 2020-08-07 0

    KACHIOFF WILLIAM G INTERIM CFO

    • Officer
    		 10,000 2020-06-01 0

    SHERWIN STEPHEN A

    • Director
    		 0 2020-05-05 0

    KARBE FRANK

    • Director
    		 0 2020-05-05 0

    MACK DAVID HENRY

    • Director
    		 0 2020-05-05 0

    OBRIEN STEPHANIE MONAGHAN

    • Director
    		 0 2020-05-05 0

    VAN ELSAS ANDREA CHIEF SCIENTIFIC OFFICER

    • Officer
    		 438,367 2020-02-25 0

    WELCH JAMES H SEE REMARKS

    • Officer
    		 0 2019-07-15 0

    LEW JENNIFER CHIEF FINANCIAL OFFICER

    • Officer
    		 321,173 2019-05-01 0

    HOTH DANIEL FLOYD JR INTERIM CHIEF MEDICAL OFFICER

    • Officer
    		 0 2018-11-29 0

    SACKS NATALIE CHIEF MEDICAL OFFICER

    • Officer
    		 173,720 2018-09-12 0

    MCCORMICK FRANK

    • Director
    		 0 2018-06-06 0

    CHAN GERALD

    • Director
    		 0 2018-06-06 0

    SCHAFER GREGORY W CHIEF OPERATING OFFICER

    • Officer
    		 254,062 2018-01-25 0

    MORNINGSIDE VENTURE (VI) INVESTMENTS LTD

    • 10% Owner
    		 9,305,532 2017-12-31 0

    BROCKSTEDT DIRK G. EVP OF RESEARCH AND DEV.

    • Officer
    		 124,603 2017-12-29 0

    DUBENSKY THOMAS W. CHIEF SCIENTIFIC OFFICER

    • Officer
    		 39,900 2017-08-10 0

    ROGERS JOHN E. AND LOIS A.

    • 10% Owner
    		 6,157,159 2015-04-20 0

    ULTIMATE KEEN LTD

    • 10% Owner
    		 5,602,499 2015-04-20 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    CHINOOK THERAPEUTICS INC KDNY 2023-08-11 22:15:04 UTC 4.2881 1.0319 1800000
    CHINOOK THERAPEUTICS INC KDNY 2023-08-11 21:45:04 UTC 4.2881 1.0319 1800000
    CHINOOK THERAPEUTICS INC KDNY 2023-08-11 21:15:04 UTC 4.2881 1.0319 1800000
    CHINOOK THERAPEUTICS INC KDNY 2023-08-11 20:45:04 UTC 4.2881 1.0319 1800000
    CHINOOK THERAPEUTICS INC KDNY 2023-08-11 20:15:05 UTC 4.2881 1.0319 1800000
    CHINOOK THERAPEUTICS INC KDNY 2023-08-11 19:45:03 UTC 4.2881 1.0319 1800000
    CHINOOK THERAPEUTICS INC KDNY 2023-08-11 19:15:04 UTC 4.2881 1.0319 1800000
    CHINOOK THERAPEUTICS INC KDNY 2023-08-11 18:45:04 UTC 4.2881 1.0319 1800000
    CHINOOK THERAPEUTICS INC KDNY 2023-08-11 18:15:04 UTC 4.2881 1.0319 1800000
    CHINOOK THERAPEUTICS INC KDNY 2023-08-11 17:45:04 UTC 4.2881 1.0319 1800000
    CHINOOK THERAPEUTICS INC KDNY 2023-08-11 17:15:04 UTC 4.2881 1.0319 1800000
    CHINOOK THERAPEUTICS INC KDNY 2023-08-11 16:45:04 UTC 4.2889 1.0211 1800000
    CHINOOK THERAPEUTICS INC KDNY 2023-08-11 16:15:04 UTC 4.2889 1.0211 1800000
    CHINOOK THERAPEUTICS INC KDNY 2023-08-11 15:45:04 UTC 4.2889 1.0211 1800000
    CHINOOK THERAPEUTICS INC KDNY 2023-08-11 15:15:04 UTC 4.2889 1.0211 1800000
    CHINOOK THERAPEUTICS INC KDNY 2023-08-11 14:45:04 UTC 4.884 0.426 1800000
    CHINOOK THERAPEUTICS INC KDNY 2023-08-11 14:15:04 UTC 4.884 0.426 1800000
    CHINOOK THERAPEUTICS INC KDNY 2023-08-11 13:45:04 UTC 4.884 0.426 1800000
    CHINOOK THERAPEUTICS INC KDNY 2023-08-11 13:15:03 UTC 4.884 0.426 1800000
    CHINOOK THERAPEUTICS INC KDNY 2023-08-11 12:45:05 UTC 4.884 0.426 1900000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments